All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CAN10
Therapeutic Area: Dermatology Product Name: CAN10
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Cantargia AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 26, 2020
Details:
CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: BT-001
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Transgene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The poster presentation at the SITC 35th Anniversary Annual Meeting outlines BT-001’s unique multifunctional properties combining potent oncolytic activities with the production of high intra-tumoral concentrations of an anti-CTLA-4 antibody and GM-CSF.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1206,Rituximab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Presentation includes preliminary data from a Phase I/IIa trial of BI-1206 in combination with rituximab in patients with follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) who have relapsed or are refractory to rituximab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1808,Pembrolizumab
Therapeutic Area: Oncology Product Name: BI-1808
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The study will explore the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent and in combination with Keytruda® in patients with ovarian cancer, non-small cell lung cancer and cutaneous T-cell lymphoma (CTCL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1206,Pembrolizumab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: CASI Pharmaceuticals
Deal Size: $88.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement October 27, 2020
Details:
Under the terms of the agreement, BioInvent and CASI will develop BI-1206 in both liquid and solid cancers, with CASI responsible for commercialization in China and associated markets.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DS-1055
Therapeutic Area: Oncology Product Name: DS-1055
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo Co Ltd
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 22, 2020
Details:
BioInvent has received the millstone payment in connection to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant (GARP) directed antibody. The antibody DS-1055 was discovered by Daiichi Sankyo and targets GARP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1808
Therapeutic Area: Oncology Product Name: BI-1808
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
Details:
Abstract titled "Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy", will be presented at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1206,Pembrolizumab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
BioInvent's lead pipeline candidate BI-1206 is a first-in-class monoclonal antibody that targets FcγRIIB - the only inhibitory Fcγ receptor that acts as a "brake" on the innate immune system - to unleash antibody-mediated reactivation of the immune response against cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1808,Pembrolizumab
Therapeutic Area: Oncology Product Name: BI-1808
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
The study will explore the safety, tolerability, and potential signs of efficacy of BI-1808 as a single agent and in combination with KEYTRUDA® in patients with ovarian cancer, non-small cell lung cancer and cutaneous T cell lymphoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BI-1206,Pembrolizumab
Therapeutic Area: Oncology Product Name: BI-1206
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
The objective of this trial is to explore the safety and tolerability profile of the combination of BI-1206 with KEYTRUDA, to characterize the pharmacokinetic/pharmacodynamic (PK/PD) profile and to determine the recommended dose of BI-1206 when combined with KEYTRUDA.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
